We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Machine-Learning Model Predicts Preeclampsia in Late Pregnancy

By HospiMedica International staff writers
Posted on 10 Mar 2026

Preeclampsia is a serious pregnancy complication marked by the sudden onset of high blood pressure before delivery. More...

Affecting approximately 2% to 8% of pregnancies worldwide, the condition can lead to severe health risks for both the parent and the baby if not detected and managed promptly. While early screening tools exist, predicting cases that develop later in pregnancy remains challenging. Researchers have now developed a machine-learning model designed to estimate preeclampsia risk during the later stages of pregnancy.

The model, developed by researchers at Weill Cornell Medicine (New York, NY, USA), in collaboration with NewYork-Presbyterian (New York, NY, USA), analyzes electronic health record (EHR) data collected during the third trimester to generate continuously updated predictions of preeclampsia risk. Unlike earlier tools that provide a single early estimate, the system recalculates risk as new clinical information becomes available.

The research team trained the machine-learning model using data from 35,895 pregnancies at NewYork-Presbyterian/Weill Cornell Medical Center between October 2020 and May 2025. They then validated the model using additional datasets from 8,664 pregnancies at NewYork-Presbyterian Lower Manhattan Hospital and 14,280 pregnancies at NewYork-Presbyterian Brooklyn Methodist Hospital. The model showed its strongest predictive performance at approximately 34 weeks of pregnancy, providing clinicians with valuable lead time before delivery.

Among the most influential predictive factors were blood pressure measurements, which remained the strongest indicator of risk. Earlier in the third trimester, abnormal blood test results—potentially reflecting placental dysfunction—were also associated with increased risk. The study, published in JAMA Network Open, found that later in pregnancy, patient age and white blood cell counts became more important predictors, suggesting that inflammatory processes may contribute to the condition at this stage.

By continuously updating predictions using real-time clinical data, the model may help clinicians identify patients at elevated risk of preeclampsia during late pregnancy. Earlier detection could allow physicians to intensify monitoring, manage blood pressure more aggressively, and make informed decisions about delivery timing to protect maternal and fetal health. Researchers note that further studies are needed to better understand whether different forms of preeclampsia arise from distinct biological causes, such as placental dysfunction or systemic inflammation.

Related Links:
Weill Cornell Medicine
NewYork-Presbyterian


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Desk Aneroid Sphyg
Diagnostix 750D+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.